Penumbra Return on Tangible Equity 2014-2022 | PEN
Current and historical return on tangible equity values for Penumbra (PEN) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Penumbra Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2022-09-30 |
$-0.03B |
$0.73B |
-4.36% |
| 2022-06-30 |
$-0.02B |
$0.72B |
-2.87% |
| 2022-03-31 |
$-0.01B |
$0.71B |
-1.03% |
| 2021-12-31 |
$0.00B |
$0.70B |
0.75% |
| 2021-09-30 |
$0.03B |
$0.67B |
5.29% |
| 2021-06-30 |
$0.02B |
$0.66B |
2.55% |
| 2021-03-31 |
$-0.00B |
$0.63B |
-0.81% |
| 2020-12-31 |
$-0.02B |
$0.62B |
-2.81% |
| 2020-09-30 |
$-0.01B |
$0.60B |
-1.89% |
| 2020-06-30 |
$0.01B |
$0.61B |
2.05% |
| 2020-03-31 |
$0.04B |
$0.46B |
8.85% |
| 2019-12-31 |
$0.05B |
$0.45B |
11.47% |
| 2019-09-30 |
$0.05B |
$0.43B |
11.20% |
| 2019-06-30 |
$0.02B |
$0.42B |
4.04% |
| 2019-03-31 |
$0.01B |
$0.40B |
3.09% |
| 2018-12-31 |
$0.01B |
$0.39B |
1.57% |
| 2018-09-30 |
$0.01B |
$0.37B |
2.12% |
| 2018-06-30 |
$0.03B |
$0.39B |
7.25% |
| 2018-03-31 |
$0.01B |
$0.38B |
3.26% |
| 2017-12-31 |
$0.00B |
$0.37B |
1.09% |
| 2017-09-30 |
$-0.01B |
$0.35B |
-2.05% |
| 2017-06-30 |
$0.01B |
$0.37B |
1.58% |
| 2017-03-31 |
$0.01B |
$0.37B |
3.50% |
| 2016-12-31 |
$0.02B |
$0.27B |
5.96% |
| 2016-09-30 |
$0.02B |
$0.25B |
7.40% |
| 2016-06-30 |
$0.01B |
$0.25B |
2.53% |
| 2016-03-31 |
$0.00B |
$0.24B |
1.14% |
| 2015-12-31 |
$0.00B |
$0.23B |
0.87% |
| 2015-06-30 |
$-0.00B |
|
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Instruments Manufacturing |
$9.289B |
$0.748B |
|
Penumbra, Inc. is an interventional therapies company. It designs, develops, manufactures and markets medical devices. The company's portfolio of products primarily addresses neuro and peripheral vascular medical conditions and clinical needs. Neuro products include Neurovascular Access, Neuron Access System, BENCHMARK Intracranial Access System, Penumbra System, 3D, Penumbra Coil 400, Penumbra SMART Coil and LIBERTY stent. Peripheral vascular products include Ruby Coil System, Penumbra Occlusion Device and Indigo System. It operates primarily in U.S., Europe, Canada and Australia. Penumbra, Inc. is headquartered in Alameda, California.
|
